Search
Cidofovir
go.drugbank.com/drugs/DB00369ApprovedInvestigational[FDA label] It was manufactured by _Gilead_ and initially approved by the FDA in 1996, but has since been discontinued.[L6223]
Temozolomide
go.drugbank.com/drugs/DB00853ApprovedInvestigational[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow … It is currently marketed under the trademark TEMODAR® by Merck.[L32033]
Sparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigational[L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … [A257330] In February 2023, the use of sparsentan to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression was approved by the FDA under
Categories: Agents Acting on the Renin-Angiotensin SystemEtuvetidigene Autotemcel
go.drugbank.com/drugs/DB17593ApprovedInvestigational[L54698] First approved by the FDA on December 9, 2025, etuvetidigene autotemcel is used to treat Wiskott–Aldrich syndrome (WAS) in selected pediatric and adult patients. … [L54693] WAS is a rare X-linked disorder caused by a mutation in the gene encoding the WAS protein, leading to a compromised immune system.
Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigational[L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard … [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.
Isoprenaline
go.drugbank.com/drugs/DB01064ApprovedInvestigationalIsoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion … [L33204] Isoprenaline was granted FDA approval on 19 February 1948.[L33155]
Categories: Non-selective Beta-adrenergic AgonistsSynonyms: N-Isopropylnoradrenaline, N-IsopropylnorepinephrineEmicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalThe ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable hemostatic efficacy produced by previous Factor VII agents. … Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co.
Thioproperazine
go.drugbank.com/drugs/DB01622ApprovedIt is virtually without antiserotonin and hypotensive action and has no antihistaminic property. … It is used for the treatment of all types of acute and chronic schizophrenia, including those which did not respond to the usual neuroleptics; manic syndromes.
Synonyms: N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]phenothiazine-2-sulfonamide, N,N-Dimethyl-10-[3-(4-methyl-1-piperazinyl)propyl]-10H-phenothiazine-2-sulfonamideArtemether
go.drugbank.com/drugs/DB06697ApprovedInvestigational</i> and may be used to treat infections caused by <i>P. falciparum</i> and unidentified <i>Plasmodium</i> species, including infections acquired in chloroquine-resistant areas. … Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy.
Olmesartan
go.drugbank.com/drugs/DB00275ApprovedInvestigationalARBs have been shown to have a protective effect on the heart by improving cardiac function, reducing afterload, increasing cardiac output and preventing ventricular hypertrophy and remodelling. … [A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882]
Mixtures: OPENVAS CO, ALMETEC-COCategories: Agents Acting on the Renin-Angiotensin System